Chief Commercial Officer Of MiMedx Group Sold 71% Of Their Shares

We'd be surprised if MiMedx Group, Inc. (NASDAQ:MDXG) shareholders haven't noticed that the Chief Commercial Officer, Kimberly Maersk-Moller, recently sold US$432k worth of stock at US$7.42 per share. Equally important, that sale actually reduced their holding by a full 71% which hardly makes us feel bullish about the stock.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

The Last 12 Months Of Insider Transactions At MiMedx Group

Over the last year, we can see that the biggest insider purchase was by CEO & Director Joseph Capper for US$1.3m worth of shares, at about US$6.34 per share. We do like to see buying, but this purchase was made at well below the current price of US$7.48. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

All up, insiders sold more shares in MiMedx Group than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

Check out our latest analysis for MiMedx Group

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Insider Ownership Of MiMedx Group

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. MiMedx Group insiders own about US$19m worth of shares. That equates to 1.7% of the company. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Do The MiMedx Group Insider Transactions Indicate?

An insider sold MiMedx Group shares recently, but they didn't buy any. Despite some insider buying, the longer term picture doesn't make us feel much more positive. Insiders own shares, but we're still pretty cautious, given the history of sales. So we'd only buy after careful consideration. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing MiMedx Group. While conducting our analysis, we found that MiMedx Group has 2 warning signs and it would be unwise to ignore these.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.